Given the pivotal role of IR in glucotoxicity and lipotoxicity, therapies that modulate incretin pathways, particularly glucagon-like peptide-1 (GLP-1) receptor agonists, may attenuate hepatic DNL and improve peripheral insulin sensitivity indirectly through weight loss, enhanced glycemic control, and reduced inflammatory tone [34]
Pregnancy and planned pregnancy are also contraindications, and patients should stop these medications well before any planned pregnancy
She encouraged industry to solve for the associated problems, by calling out protein content and adjust portion sizes, but dont market it as GLP-1 friendly
Earlier this month, Novo Nordisk also took steps to protect its position in the weight-loss market by going after knock-off versions of its drugs
No bioavailability studies
They first analyzed data from an earlier long COVID study involving 90 people hospitalized with COVID-19, including 11 with type 2 diabetes and 79 without